Thomas Karlas, Sebastian Beer, Jonas Babel, Harald Busse, Alexander Schaudinn, Nicolas Linder, Johannes Wiegand, David Petroff – 19 January 2017
Salvatore Petta, Vincent Way‐Sun Wong, Victor de Ledinghen – 19 January 2017
Anders Boyd, Patrick Miailhes, Karine Lacombe, Fabien Zoulim – 19 January 2017
Iliana Doycheva, Kymberly D. Watt, Naim Alkhouri – 19 January 2017 – Nonalcoholic fatty liver disease (NAFLD) is a significant health burden in adolescents and young adults (AYAs) which has substantially risen in prevalence over the last decades. The occurrence of NAFLD parallels high rates of obesity and metabolic syndrome in this age group, with unhealthy lifestyle also playing an independent role. Genetic factors, sex, and ethnicity should be considered in a risk stratification model.
Antoni Sabate, Annabel Blasi – 19 January 2017
Veeral H. Ajmera, Norah A. Terrault, Stephen A. Harrison – 18 January 2017 – Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied.
Feng Su, George N. Ioannou – 18 January 2017
Thomas R. O'Brien, Shyam Kottilil, Jordan J. Feld, Timothy R. Morgan, Ruth M. Pfeiffer – 18 January 2017
Zongwen Shuai, Jinjun Wang, Madhu Badamagunta, Jinjung Choi, Guoxiang Yang, Weici Zhang, Thomas P. Kenny, Kathryn Guggenheim, Mark J. Kurth, Aftab A. Ansari, John Voss, Ross L. Coppel, Pietro Invernizzi, Patrick S.C. Leung, M. Eric Gershwin – 18 January 2017 – The identification of environmental factors that lead to loss of tolerance has been coined the holy grail of autoimmunity.
Càndid Villanueva, Isabel Graupera, Carles Aracil, Edilmar Alvarado, Josep Miñana, Ángela Puente, Virginia Hernandez‐Gea, Alba Ardevol, Oana Pavel, Alan Colomo, Mar Concepción, María Poca, Xavier Torras, Josep M. Reñe, Carlos Guarner – 18 January 2017 – Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB.